<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343991</url>
  </required_header>
  <id_info>
    <org_study_id>BBB001</org_study_id>
    <secondary_id>215600</secondary_id>
    <nct_id>NCT02343991</nct_id>
  </id_info>
  <brief_title>Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound</brief_title>
  <official_title>A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of BBB disruption using transcranial&#xD;
      MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to&#xD;
      increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the&#xD;
      ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety&#xD;
      of this type of treatment as the basis for later studies to evaluate its clinical efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Device and Procedure related adverse events</measure>
    <time_frame>At the time of ExAblate transcranial procedure</time_frame>
    <description>To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Device and Procedure related adverse events</measure>
    <time_frame>At the time of ExAblate transcranial procedure</time_frame>
    <description>To evaluate the incidence and severity of adverse events (AEs) associated with the ExAblate transcranial treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Transcranial ExAblate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MR Guided Focused Ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial ExABlate</intervention_name>
    <description>MR Guided Focused Ultrasound</description>
    <arm_group_label>Transcranial ExAblate</arm_group_label>
    <other_name>ExAblate</other_name>
    <other_name>TcMRgFUS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women.&#xD;
&#xD;
          -  Age between 18 and 70 years, inclusive.&#xD;
&#xD;
          -  Able and willing to give informed consent.&#xD;
&#xD;
          -  Size of the targeted portion of the tumour (i.e. prescribed ROT) is less than 2.5 cm&#xD;
             in diameter (16 cm3). The non-targeted tumour tissue may exceed the targeted volume.&#xD;
&#xD;
          -  Karnofsky rating 70-100&#xD;
&#xD;
          -  ASA score 1-3.&#xD;
&#xD;
          -  Able to communicate sensations during the ExAblate MRgFUS procedure.&#xD;
&#xD;
          -  Able to attend all study visits (i.e., life expectancy of at least 3 months).&#xD;
&#xD;
          -  At least 14 days passed since last brain surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The sonication pathway to the tumour involves:&#xD;
&#xD;
             i. More than 30% of the skull area traversed by the sonication pathway is covered by&#xD;
             scars, scalp disorders (e.g., eczema), or atrophy of the scalp ii. Clips or other&#xD;
             metallic implanted objects in the skull or the brain, except shunts&#xD;
&#xD;
          -  The subject presents with symptoms and signs of increased intracranial pressure (e.g.,&#xD;
             headache, nausea, vomiting, lethargy, and papilledema)&#xD;
&#xD;
          -  Cardiac disease or unstable hemodynamics including:&#xD;
&#xD;
             i. Documented myocardial infarction within six months of enrolment ii. Unstable angina&#xD;
             on medication iii. Congestive heart failure iv. Left ventricular ejection fraction&#xD;
             below the lower limit of normal v. History of a hemodynamically unstable cardiac&#xD;
             arrythmia vi. Cardiac pacemaker&#xD;
&#xD;
          -  Severe hypertension (diastolic BP &gt; 100 on medication)&#xD;
&#xD;
          -  Anti-coagulant therapy, or medications known to increase risk of hemorrhage,&#xD;
             (e.g.:ASA, non-steroidal anti-inflammatory drugs (NSAIDs), statins)&#xD;
&#xD;
          -  History of a bleeding disorder, coagulopathy or with a history of spontaneous tumour&#xD;
             hemorrhage&#xD;
&#xD;
          -  Abnormal level of platelets (&lt; 100000), PT (&gt;14) or PTT (&gt;36), and INR &gt; 1.3&#xD;
&#xD;
          -  Documented cerebral infarction within the past 12 months&#xD;
&#xD;
          -  TIA in the last 1 month&#xD;
&#xD;
          -  Cerebral or systemic vasculopathy&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  Immunosuppression (corticosteroids to prevent/treat brain edema are permitted)&#xD;
&#xD;
          -  Known sensitivity to gadolinium-DTPA&#xD;
&#xD;
          -  Contraindications to MRI such as non-MRI-compatible implanted devices&#xD;
&#xD;
          -  Large subjects not fitting comfortably into the MRI scanner (generally &gt;250 lbs)&#xD;
&#xD;
          -  Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia&#xD;
&#xD;
          -  Untreated, uncontrolled sleep apnea&#xD;
&#xD;
          -  Positive pregnancy test (for pre-menopausal women)&#xD;
&#xD;
          -  Known life-threatening systemic disease&#xD;
&#xD;
          -  Severely impaired renal function with estimated glomerular filtration rate &lt;30&#xD;
             mL/min/1.73m2 and/or on dialysis&#xD;
&#xD;
          -  Right to left or bi-directional cardiac shunt&#xD;
&#xD;
          -  Previous full course of doxorubicin chemotherapy&#xD;
&#xD;
          -  Allergy to eggs or egg products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

